Search results for "connective tissue disease"

showing 10 items of 874 documents

Innate lymphoid cells, precursors and plasticity

2016

Innate lymphoid cells (ILC) have only recently been recognized as a separate entity of the lymphoid lineage. Their subpopulations share common characteristics in terms of early development and major transcriptional circuitry with their related cousins of the T cell world. It is currently hypothesized that ILCs constitute an evolutionary older version of the lymphoid immune system. They are found at all primary entry points for pathogens such as mucosal surfaces of the lung and gastrointestinal system, the skin and the liver, which is the central contact point for pathogens that breach the intestinal barrier and enter the circulation. There, ILC contribute to the first line defense as well a…

0301 basic medicineCellular differentiationT cellCell PlasticityImmunologyBiology03 medical and health sciences0302 clinical medicineImmune systemCell PlasticitymedicineAnimalsHumansImmunology and AllergyCell Lineageskin and connective tissue diseasesPrecursor Cells T-LymphoidRegeneration (biology)Innate lymphoid cellGene Expression Regulation DevelopmentalCell DifferentiationT-Lymphocytes Helper-InducerImmunity InnateLymphocyte Subsetsbody regionsPhenotype030104 developmental biologyLymphatic systemmedicine.anatomical_structureImmunologyStem cellBiomarkersSignal TransductionT-Lymphocytes CytotoxicTranscription Factors030215 immunologyImmunology Letters
researchProduct

Advances in the treatment of cutaneous lupus erythematosus.

2016

Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used “off-label”, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine,…

0301 basic medicineCyclophosphamideDiscoid lupus erythematosusAzathioprineAntibodiesEtanerceptPolyethylene Glycols03 medical and health sciencesLupus Erythematosus DiscoidRheumatologyimmune system diseasesChloroquineMedicineHumansLupus Erythematosus SystemicMolecular Targeted TherapyPrecision Medicineskin and connective tissue diseasesRandomized Controlled Trials as TopicB-LymphocytesLupus erythematosusbusiness.industryInterleukin-6Anti-Inflammatory Agents Non-SteroidalHydroxychloroquinemedicine.diseaseBelimumab030104 developmental biologyImmunologyInterferonsbusinessBiomarkersAnti-SSA/Ro autoantibodiesmedicine.drugSignal TransductionLupus
researchProduct

Functional characterization of circulating tumor cells (CTCs) from metastatic ER+/HER2− breast cancer reveals dependence on HER2 and FOXM1 for endocr…

2021

Simple Summary Acquired endocrine resistance and late recurrence in patients with ER+/HER2− breast cancer are complex and not fully understood. Here, we evaluated mechanisms of acquired resistance in circulating tumor cells (CTCs) from an ER+/HER2− breast cancer patient who initially responded but later progressed under endocrine treatment. We found a switch from ERα-dependent to HER2-dependent and ERα-independent expression of FOXM1, which may enable disseminated ER+/HER2− cells to re-initiate tumor cell growth and metastasis formation in the presence of endocrine treatment. We found that NFkB signaling sustains HER2 and FOXM1 expression in CTCs in the presence of ERα inhibitors suggesting…

0301 basic medicineDrugLife sciences; biologyCancer Researchmedia_common.quotation_subjectTumor cellslcsh:RC254-282Article03 medical and health sciencesTherapeutic approach0302 clinical medicineCirculating tumor cellBreast cancerHER2-dependent FOXM1 expressionddc:570ER+/HER2− circulating tumor cellsMedicineEndocrine systemskin and connective tissue diseasesmedia_commonER+/HER2��� circulating tumor cellsbusiness.industryendocrine therapy resistancelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncologyApoptosis030220 oncology & carcinogenesisFOXM1Cancer researchbusiness
researchProduct

p73 is required for ependymal cell maturation and neurogenic SVZ cytoarchitecture

2015

The adult subventricular zone (SVZ) is a highly organized microenvironment established during the first postnatal days when radial glia cells begin to transform into type B-cells and ependymal cells, all of which will form regenerative units, pinwheels, along the lateral wall of the lateral ventricle. Here, we identify p73, a p53 homologue, as a critical factor controlling both cell-type specification and structural organization of the developing mouse SVZ. We describe that p73 deficiency halts the transition of the radial glia into ependymal cells, leading to the emergence of immature cells with abnormal identities in the ventricle and resulting in loss of the ventricular integrity. p73-de…

0301 basic medicineEpendymal CellCiliumNeurogenesisSubventricular zoneBiology03 medical and health sciencesCellular and Molecular NeuroscienceLateral ventricles030104 developmental biologymedicine.anatomical_structureDevelopmental NeuroscienceCytoarchitectureCiliogenesismedicineskin and connective tissue diseasesEpendymaneoplasmsNeuroscienceDevelopmental Neurobiology
researchProduct

Low-energy extracorporeal shockwave therapy (ESWT) improves metaphyseal fracture healing in an osteoporotic rat model.

2017

Purpose As result of the current demographic changes, osteoporosis and osteoporotic fractures are becoming an increasing social and economic burden. In this experimental study, extracorporeal shock wave therapy (ESWT), was evaluated as a treatment option for the improvement of osteoporotic fracture healing. Methods A well-established fracture model in the metaphyseal tibia in the osteoporotic rat was used. 132 animals were divided into 11 groups, with 12 animals each, consisting of one sham-operated group and 10 ovariectomized (osteoporotic) groups, of which 9 received ESWT treatment. Different energy flux intensities (0.15 mJ/mm2, 0.35 mJ/mm2, or 0.55 mJ/mm2) as well as different numbers o…

0301 basic medicineExtracorporeal Shockwave TherapyCritical Care and Emergency Medicinemedicine.medical_treatmentOsteoporosisTest StatisticsDentistryGene Expressionlcsh:MedicineRats Sprague-Dawley0302 clinical medicineMathematical and Statistical TechniquesAnimal CellsMedicine and Health SciencesReproductive System ProceduresConnective Tissue Diseaseslcsh:ScienceMusculoskeletal SystemTrauma MedicineConnective Tissue CellsFracture Healing030222 orthopedicsMultidisciplinaryBiomechanicsBone FractureConnective TissueExtracorporeal shockwave therapyPhysical SciencesOvariectomized ratFemaleAnatomyCellular TypesTraumatic InjuryStatistics (Mathematics)Research ArticleOvariectomySurgical and Invasive Medical ProceduresBone healingResearch and Analysis Methods03 medical and health sciencesRheumatologymedicineGeneticsAnimalsTibiaStatistical MethodsSkeletonAnalysis of VarianceOsteoblastsSurgical ExcisionTibiabusiness.industrylcsh:RBiology and Life SciencesBone fractureCell Biologymedicine.diseaseRatsDisease Models Animal030104 developmental biologyBiological TissueAdjunctive treatmentOsteoporosislcsh:QbusinessOsteoporotic FracturesMathematicsPLoS ONE
researchProduct

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

2020

Abstract HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of m…

0301 basic medicineFulvestrantCombination therapybusiness.industryEstrogen receptormedicine.diseaseMetastatic breast cancer03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncologyTrastuzumab030220 oncology & carcinogenesisNeratinibmedicineCancer researchSignal transductionskin and connective tissue diseasesbusinessmedicine.drugCancer Discovery
researchProduct

Early inflammatory players in cutanous fibrosis.

2017

Systemic sclerosis (SSc) is one of the most complex systemic autoimmune diseases with multi-organ involvement and heterogeneous clinical manifestations. The exact etiology of SSc is still unknown. However, identified target structures are components of endothelial cells, the innate/adaptive immune systems and fibroblasts, resulting in the hallmarks of the disease in form of inflammation/autoimmunity, vasculopathy and fibrosis of the skin and internal organs. There has been a large body of evidence that the adaptive immune system with autoreactive T and B cells producing autoantibodies plays a central role in the pathogenesis of SSc but the role of earlier pathogenic processes involving the …

0301 basic medicineInflammationAutoimmunityDermatologyBiologymedicine.disease_causeBiochemistryAutoimmunity03 medical and health sciences0302 clinical medicineImmune systemmedicineLeukocytesHumansPlatelet activationskin and connective tissue diseasesMolecular BiologyAutoantibodiesSkinAutoimmune diseaseInflammationImmunity CellularInnate immune systemScleroderma Systemicintegumentary systemInnate lymphoid cellEndothelial CellsFibroblastsmedicine.diseaseAcquired immune systemPlatelet ActivationFibrosisImmunity Innate030104 developmental biology030220 oncology & carcinogenesisImmunologymedicine.symptomImmunosuppressive AgentsJournal of dermatological science
researchProduct

Cytokine profile of breast cell lines after different radiation doses

2017

Purpose: Ionizing radiation (IR) treatment activates inflammatory processes causing the release of a great amount of molecules able to affect the cell survival. The aim of this study was to analyze the cytokine signature of conditioned medium produced by non-tumorigenic mammary epithelial cell line MCF10A, as well as MCF7 and MDA-MB-231 breast cancer cell lines, after single high doses of IR in order to understand their role in high radiation response. Materials and methods: We performed a cytokine profile of irradiated conditioned media of MCF10A, MCF7 and MDA-MB-231 cell lines treated with 9 or 23 Gy, by Luminex and ELISA analyses. Results: Overall, our results show that both 9 Gy and 23 …

0301 basic medicineIonizing radiationRadiology Nuclear Medicine and ImagingCell SurvivalCytokine profileBreast NeoplasmsInflammationRadiationRadiation ToleranceIonizing radiation03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerCell Line TumormedicinecytokineHumansskin and connective tissue diseasesCell survivalRadiological and Ultrasound TechnologyChemistrybreast cancer cytokines inflammation Ionizing radiation Breast Neoplasms Cell Line Tumor Cell Survival Culture Media Conditioned Dose-Response Relationship Radiation Humans Phenotype Radiation ToleranceDose-Response Relationship Radiationmedicine.diseasecytokinesDose–response relationship030104 developmental biologyPhenotypeCell cultureinflammation030220 oncology & carcinogenesisCulture Media ConditionedImmunologyCancer researchmedicine.symptomBreast NeoplasmHuman
researchProduct

Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.

2020

Abstract HER2-positive breast cancer is currently managed with chemotherapy in combination with specific anti-HER2 therapies, including trastuzumab. However, a high percentage of patients with HER2-positive tumors do not respond to trastuzumab (primary resistance) or either recur (acquired resistance), mostly due to molecular alterations in the tumor that are either unknown or undetermined in clinical practice. Those alterations may cause the tumor to be refractory to treatment with trastuzumab, promoting tumor proliferation and metastasis. Using continued exposure of a HER2-positive cell line to trastuzumab, we generated a model of acquired resistance characterized by increased expression …

0301 basic medicineMAPK/ERK pathwayCancer ResearchMAP Kinase Signaling SystemReceptor ErbB-2medicine.medical_treatmentMice NudeApoptosisBreast NeoplasmsCCL5Metastasis03 medical and health sciencesMice0302 clinical medicineBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabmedicineBiomarkers TumorTumor Cells CulturedGene silencingAnimalsHumansskin and connective tissue diseasesAutocrine signallingneoplasmsChemokine CCL5Neoadjuvant therapyCell Proliferationbusiness.industryGene Expression ProfilingTrastuzumabmedicine.diseaseXenograft Model Antitumor AssaysGene Expression Regulation NeoplasticAutocrine Communication030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchFemalebusinessmedicine.drugMolecular cancer therapeutics
researchProduct

Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling

2020

The epidermal growth factor receptor (EGFR) interacts with various downstream molecules including phospholipase C (PLC)/protein kinase C (PKC), Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/GSK-3, Jak/STAT and others. Often these pathways are deregulated in human malignancies such as breast cancer. Various therapeutic approaches to inhibit the activity of EGFR family members including small molecule inhibitors and monoclonal antibodies (MoAb) have been developed. A common problem with cancer treatments is the development of drug-resistance. We examined the effects of a conditionally-activated EGFR (v-Erb-B:ER) on the resistance of breast cancer cells to commonly used chemotherapeutic drugs such as doxorub…

0301 basic medicineMAPK/ERK pathwayEGFRvIIICancer ResearchEGFREstrogen receptorAntineoplastic AgentsBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerCell Line TumorGeneticsHumansMedicinePTENEpidermal growth factor receptorskin and connective tissue diseasesMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwaybiologybusiness.industryCancermedicine.diseaseErbB Receptors030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDrug resistancebiology.proteinCancer researchMolecular MedicineFemalebusinessSignal TransductionV-Erb-B
researchProduct